Suppr超能文献

非小细胞肺癌伴同步多发磨玻璃肺结节患者的驱动基因突变差异较大。

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.

机构信息

Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, P.R.China.

Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, P.R.China.

出版信息

J Thorac Oncol. 2015 May;10(5):778-783. doi: 10.1097/JTO.0000000000000487.

Abstract

BACKGROUND

The aim of this study was to investigate the discordance rates of eight known driver mutations among multiple matched intrapulmonary ground-glass nodules (GGNs) in non-small-cell lung cancer (NSCLC) patients.

METHODS

Tumors from 35 patients with multiple lesions resected, including confirmed NSCLC and at least one GGN, were analyzed for mutations in EGFR, KRAS, HER2, BRAF, and PIK3CA together with fusions in ALK, ROS1, and RET.

RESULTS

From 35 patients, a total of 72 lesions (60 were GGNs) were analyzed. These included nine adenocarcinoma in situ, nine minimal invasive adenocarcinoma, and 54 invasive adenocarcinoma. Among them, 33 tumor lesions (45.8 %) were found harboring EGFR mutations: 13 tumors with exon 19 deletion, 18 with L858R on exon 21, and two with both exon 19 del and L858R mutation. There were 5 tumors (6.9 %) harboring EML4-ALK fusion, four HER2 mutations (5.6%), three KRAS mutations (4.2%), one ROS1 fusion and one BRAF mutation. When we used the matched tumors to determine the intertumor discrepancy, only six out of 30 patients harbored identical mutations. The discordance rate of driver mutations was 80% (24 of 30) in those patients harboring at least one of the detected driver mutations. The median disease-free survival was 41.2 months (95% confidence interval: 35.8-52.6 months) and the median overall survival was "still not reached" in this cohort.

CONCLUSIONS

We found a high discrepancy of driver mutations among NSCLC patients with GGNs and a favorable prognosis after multiple lesions resection, which support surgical resection in this situation as a reasonable approach.

摘要

背景

本研究旨在探讨非小细胞肺癌(NSCLC)患者多个肺内磨玻璃结节(GGN)中 8 种已知驱动基因突变的不一致率。

方法

对 35 例多灶性病变切除患者的肿瘤进行 EGFR、KRAS、HER2、BRAF 和 PIK3CA 基因突变分析,以及 ALK、ROS1 和 RET 融合分析。

结果

从 35 例患者中共分析了 72 个病灶(60 个为 GGN),包括 9 例原位腺癌、9 例微浸润腺癌和 54 例浸润性腺癌。其中,33 个肿瘤病灶(45.8%)携带 EGFR 突变:13 个肿瘤存在外显子 19 缺失,18 个存在外显子 21 的 L858R 突变,2 个同时存在外显子 19 缺失和 L858R 突变。有 5 个肿瘤(6.9%)携带 EML4-ALK 融合,4 个 HER2 突变(5.6%),3 个 KRAS 突变(4.2%),1 个 ROS1 融合和 1 个 BRAF 突变。当我们使用匹配的肿瘤来确定肿瘤间的差异时,只有 30 例患者中的 6 例携带相同的突变。在至少携带一种检测到的驱动突变的患者中,驱动突变的不一致率为 80%(30 例中的 24 例)。该队列的无病生存期中位数为 41.2 个月(95%置信区间:35.8-52.6 个月),总生存期中位数仍未达到。

结论

我们发现肺 GGN 患者的 NSCLC 中存在较高的驱动基因突变不一致率,且多灶性病变切除后预后良好,支持在此情况下采用手术切除作为合理的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验